# Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

> **NCT01646814** · PHASE2 · COMPLETED · sponsor: **PLx Pharma** · enrollment: 247 (actual)

## Conditions studied

- Gastroduodenal Ulceration

## Interventions

- **DRUG:** PL2200
- **DRUG:** Aspirin tablets

## Key facts

- **NCT ID:** NCT01646814
- **Lead sponsor:** PLx Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01646814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01646814, "Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01646814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*